Feb 1 2008, 11:15 AM EST
GEN News Highlights
ImmunoGen reports that Biogen Idec submitted an IND application for a cancer drug candidate, triggering a $1.5 million milestone payment. BIIB015 comprises ImmunoGen’s cell-killing agent, DM4, linked to Biogen Idec’s Cripto-targeting antibody. Biogen Idec is developing the compound for the treatment of solid tumors that express the Cripto antigen.
In 2004, Biogen Idec licensed the exclusive right to use ImmunoGen’s maytansinoid TAP technology with antibodies that target Cripto. Besides milestone fees, ImmunoGen is also entitled to royalties on products resulting from this agreement.
ImmunoGen’s TAP technology is designed to enhance the anticancer activity of tumor-targeting mAbs. The firm’s cell-killing agents are attached to an antibody using a linker, which delivers the agent specifically to cancer cells.
While ImmunoGen uses this platform to fuel its own pipeline, it also out-licenses this technology. “We expect there to be as many as eight TAP compounds in the clinic by this summer—the five already in clinical testing plus three more compounds advancing toward the clinic,” says Mitchel Sayare, chairman and CEO.
ADVERTISEMENT
INTERVIEW:
(BIO) BANKING IN LUXEMBOURG - Interview with Robert Hewitt, Ph.D., CEO, Integrated Biobank of Luxembourg, and European Editor, Biopreservation and Biobanking (published by Mary Ann Liebert, Inc.)
...MORE
NewsArticles Blogs| Most Viewed | Most Emailed | Top Searches |
|---|---|---|
| Unclog the Innovation Bottleneck at our Nation’s Universities | ||
| (Bio) Banking in Luxembourg | ||
ADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More GEN News Highlights
Listen
Save
Comment
View All